ConductScience.org, home

Paper35779372

Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis.

Mukhtar H and 4 others. Mult Scler Relat Disord, 2022. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis. Papers, record 35779372. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35779372

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis.
PubMed
Journal
Mult Scler Relat Disord
PubMed
Year
2022
PubMed
Publication types
Letter, Meta-Analysis
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.19
iCite
Revised in PubMed
2025-07-28
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mukhtar HHumza
2Yasmeen UUzma
3Siddiqa SSania
4Sarfraz ZZouina
5Sarfraz AAzza

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Multiple SclerosisMajor topic
Multiple Sclerosis, Relapsing-RemittingMajor topic
Antibodies, Monoclonal
Crotonates
Humans
Hydroxybutyrates
Nitriles
Recurrence
Toluidines

Source PubMed

Download CSV of topics

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42704608Safety and efficacy of anti-CD20 monoclonal antibodies versus teriflunomide in relapsing multiple sclerosis: a systematic review and meta-analysis.Acta Neurol Belg2026https://conductscience.org/library/papers/42704608PubMed
41007627Anti-B Cell Strategy in Nephrotic Syndrome: Beyond Rituximab.Biomedicines2025https://conductscience.org/library/papers/41007627PubMed
36951997A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022.Naunyn Schmiedebergs Arch Pharmacol2023https://conductscience.org/library/papers/36951997PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
KRT2054474PubTator's text mininghttps://conductscience.org/library/genes/54474

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35779372

GET https://conductscience.org/api/papers/v1/35779372/authors